Manhattan Institute for Policy Research.
search  
 
Subscribe   Subscribe   MI on Facebook Find us on Twitter Find us on Instagram      
 
 
   
 
     
 

FoxNews.com

 

We Can't Lose Our Global Leadership In Medical Innovation

April 23, 2010

By Tomas J. Philipson

American solidarity with the less affluent today risks shortchanging the young tomorrow.

The health care reforms President Obama recently signed into law have been put forward as the culmination of the U.S.’s moral obligation to provide health care for those who cannot afford it. Advocates of this view embrace the European vision of social insurance, or “solidarity,” in which government-financed health care is the cornerstone of a civilized society.

As a European with dual U.S. citizenship, I’m skeptical about whether European social policies truly benefit those they are intended to help. And I’m deeply concerned that America’s embrace of the European solidarity model will come at the expense of another, ultimately a more valuable brand of solidarity: solidarity with the young and with future generations, who depend on continued medical innovations. If the U.S., in the name of funding a new universal health care entitlement, abandons its global leadership in medical innovation, we’ll be selling our future short.

European nations have set price controls or other restrictions on new drugs, diagnostics, and medical devices that limit patient access to those technologies — and limit profits for the companies that make them. Partly due to these government controls, Europe manages to spend significantly less than the U.S. does while still maintaining fairly advanced medical systems.

Has Europe found some new way to have their cake and eat it too — enjoying both lower costs and high levels of innovation?

In a word, no. Solidarity is cheap in Europe, but only because it is expensive in the U.S. The United States generates the lion’s share of global profits for medical innovators, because so far U.S. policymakers have rejected explicit price controls on private markets. For example, more than half the world’s sales of drugs occur in the U.S., even though the U.S. represents only about one-fifth of the world economy. Profits generated in the United States allow innovators across the world to fund the expensive R&D efforts that are critical for bringing innovative new medicines to market.

Countries like the United Kingdom, with just 3% of world drug sales, face very different incentives. In fact, it is in their self-interest to provide solidarity through government-controlled prices, because such a policy does not significantly affect the flow of new medicines into Britain. As long as the U.S. underwrites world innovation, E.U. member countries can “free ride” on the new flow of treatments largely paid for by American free-market policies.

However, if the U.S. were to start acting like a European country — as seems likely in the wake of health care reform and the resulting fiscal pressures to come–innovation would lessen world-wide, reducing the flow of new and valuable products both to Americans and Europeans. The U.S. faces real innovation tradeoffs in creating new health care entitlements; European countries don’t.

Proponents of American reform may still claim that it merely aims to eliminate wasteful spending. However, the consensus in the research community is that new technologies are the main source of cost-growth in the U.S., but they also generate far larger health benefits than increased spending. Waste does need to be eliminated, particularly in public programs, but it is not the primary factor driving health care inflation. Put differently, insurance plans offering 1980s technologies with the corresponding lower premiums would not survive today.

Because of the economic value of innovation, by moving toward the European government-based model of care the U.S. faces a choice between two forms of solidarity. One is the most commonly articulated version of solidarity with those who currently cannot afford care: universal coverage. It’s all about the present and the near term. The other version is solidarity towards the younger population and future generations, who will inevitably suffer from U.S.-based reforms that reduce medical innovation. It’s about the long term. In effect, American solidarity with the less affluent today risks shortchanging the young tomorrow.

This does not have to be the case. Not all consumers require equal help in accessing affordable health care. By focusing taxpayer subsidies on the poorest and sickest patients (called “means testing”), innovation can be stimulated while still offering effective care for those who cannot afford it. Government subsidies for poor people will even raise innovative returns by stimulating demand for non-existent markets, as has been the case for innovation in new treatments for HIV, largely paid for by Medicaid.

Unfortunately, the recently enacted health care reforms are taking the U.S. in the opposite direction, offering large subsidies (starting in 2014) to uninsured middle class families making up to $90,000. The subsidies will cover both private insurance premiums and out-of-pocket costs. In addition, the reforms impose more price controls by making cuts in the Medicare Advantage program that allows private insurance companies to set prices freely. These new, European-style, open-ended commitments will become unsustainable in the long run, just as some predicted (correctly) would be the case for Medicare. More importantly, the stifling of innovation will make for massive amounts of increased mortality and morbidity in the younger population as they age.

Because the most significant components of Obamacare do not take effect for several years, there is still time to reshape it, both to expand affordable safety-net coverage and encourage innovation. But first we must reject the common assumption that the only form of solidarity worth pursuing is universal coverage — the “right” for all citizens, regardless of their means, to access low-cost medical care. Instead, we must emphasize our solidarity with future generations. Whatever short-term benefits in coverage reforms might bring, our children and grandchildren will inevitably pay the price if the U.S. adopts European-style price controls at the cost of the medical innovations that have done so much for the world.

Original Source: http://www.foxnews.com/opinion/2010/04/23/tomas-philipson-obamacare-health-care-europe-medical-innovation/

 

 
PRINTER FRIENDLY
 
LATEST FROM OUR SCHOLARS

5 Reasons Janet Yellen Shouldn’t Focus On Income Inequality
Diana Furchtgott-Roth, 10-20-14

Why The Comptroller Race Matters
Nicole Gelinas, 10-20-14

Obama Should Have Picked “Ebola Czar” With Public-Health Experience
Paul Howard, 10-18-14

Success Of Parent Trigger Is Unclear­—Just As Foes Want
Ben Boychuk, 10-18-14

On Obamacare's Second Birthday, Whither The HSA?
Paul Howard, 10-16-14

You Can Repeal Obamacare And Keep Kentucky's Insurance Exchange
Avik Roy, 10-15-14

Are Private Exchanges The Future Of Health Insurance?
Yevgeniy Feyman, 10-15-14

This Nobel Prize-Worthy Economist Figured Out How To Destroy Terrorism
Diana Furchtgott-Roth, 10-15-14

 
 
 

The Manhattan Institute, a 501(c)(3), is a think tank whose mission is to develop and disseminate new ideas
that foster greater economic choice and individual responsibility.

Copyright © 2014 Manhattan Institute for Policy Research, Inc. All rights reserved.

52 Vanderbilt Avenue, New York, N.Y. 10017
phone (212) 599-7000 / fax (212) 599-3494